| Dear Voornaam, Welcome to your November newsletter. In October, we enjoyed a fascinating few days at our first ever Engineering and Physical Sciences in Oncology Conference in partnership with AACR. Over 230 international delegates and speakers gathered in London to showcase fresh perspectives on the biggest challenges in cancer research and engage in dialogue and debate between disciplines. We also saw the launch of 2 CRUK initiatives that will drive a sea-change in early detection and radiotherapy research: the International Alliance for Cancer Early Detection (ACED), and Cancer Research UK RadNet, which together represent a 106m investment from CRUK. Read more about these initiatives, new Grand Challenge-funded research, and our new entrepreneurial programmes below. Kind regards, Iain Foulkes Executive Director, Research & Innovation Cancer Research UK |
|
|---|
|
|---|
|
|
| | | EARLY CAREER RESEARCHER, MID-CAREER RESEARCHER, ESTABLISHED INDEPENDENT RESEARCHER, CLINICIAN, NON-CLINICAL RESEARCHER 06 December 2019 |
|
|---|
|
|---|
| | | POSTDOCTORAL RESEARCHERS, PROFESSORS, CLINICIANS, START-UPS 07 January 2020 |
|
|---|
|
|---|
| | | ALL CAREER STAGES 10 January 2020 |
|
|---|
|
|---|
| | | CLINICIAN, NON-CLINICAL RESEARCHER, EARLY CAREER RESEARCHER, MID-CAREER RESEARCHER, ESTABLISHED INDEPENDENT RESEARCHER 30 January 2020 |
|
|---|
|
|---|
|
|
 NEW TRANSATLANTIC ALLIANCE TO ACCELERATE CANCER EARLY DETECTION RESEARCH On 21 October, we launched the International Alliance for Cancer Early Detection (ACED) to help accelerate and revolutionise research in the early detection of cancers through collaboration between the UK and the US. ACED is a partnership between Cancer Research UK, Canary Center at Stanford University, the University of Cambridge, Knight Cancer Institute at OHSU, UCL and the University of Manchester. Scientists in the Alliance will work together at the forefront of technological innovation to translate research into realistic ways to improve cancer diagnosis, which can be implemented into health systems. |
|
|---|
|  CRUK RADNET SETS UP THE UK TO LEAD NEXT-GENERATION RADIOTHERAPY RESEARCH On Monday we announced a 56m investment in CRUK RadNet, our largest ever investment in radiotherapy research. CRUK RadNet is a national network of 7 centres of excellence in radiation research. It unites the universities of Cambridge, Glasgow, Leeds, Manchester and Oxford, the CRUK City of London Centre and the Institute of Cancer Research in partnership with the Royal Marsden NHS Foundation Trust, London. The network will accelerate investigation into therapies including FLASH, proton beam, precision medicine and combination therapies. Of this investment, 13m will go to support new research groups and fund additional PhD students in Manchester, London and Cambridge. Additionally, a share of 4m is available to all centres for joint research projects, conferences and secondments between locations. |
|
|---|
|
|---|
|
|
| | LATEST LUNG CANCER INSIGHTS FROM OUR TRACERX STUDY Three new papers from our flagship lung study provide fresh insights into the mutational landscape of the disease. Publishing in Nature Medicine, the teams from the TRACERx Consortium identify a clonally expressed biomarker associated with mortality, examine the potential of circulating tumour cells as a predictor of relapse, and characterise the spatial heterogeneity of the T cell receptor repertoire in lung cancer. |
|
|---|
|
|---|
|
|
 LAST CHANCE TO SUBMIT YOUR IDEA FOR A GRAND CHALLENGE There are just a few weeks left to tell us your idea for a Grand Challenge. Use your unique perspective to articulate a challenge that could change the face of cancer research. Since July, weve been seeking ideas to help us shape the next round of Grand Challenges, with recent workshops taking place in Madrid, Milan, London and Edinburgh. The impact of diet, ageing and sex difference in treatment response all cropped up in recent discussion. Submit your idea by 29 November 2019. |
|
|---|
|  NEW DISCOVERIES FROM OUR GRAND CHALLENGE COMMUNITY Check out this trio of papers from our Grand Challenge teams and our scientific advisory panel member, published recently in Nature and Nature Medicine: |
|
|---|
|
|---|
|
|
 THE TOOLBOX OF THE RESEARCH ENTREPRENEUR We believe that developing and nurturing an entrepreneurial culture amongst cancer researchers in the UK can help bridge the gap between progress in medical research and translation of new findings into clinical practice. However, becoming a research entrepreneur does not come without any challenges along the way. Researchers and supporters of innovation in academia discuss the challenges and opportunities for budding entrepreneurs in cancer research including our Entrepreneurial Programmes initiative in our latest Research Feature. |
|
|---|
|  ARE YOU INTERESTED IN TRANSLATING YOUR RESEARCH TO DELIVER BENEFITS FOR PEOPLE WITH CANCER? Transforming academic discoveries into patient benefit can take many routes. Weve partnered with 2 established business accelerator providers; Panacea and Deep Science Ventures. Both programmes are currently recruiting entrepreneurially-minded researchers, offering training, mentoring and resources to successfully translate their discoveries. The 2 programmes have differing models, which can benefit you whether you have a specific idea you would like to develop, or simply have an interest in becoming an entrepreneur. |
|
|---|
|
|---|
|
|
 ESTABLISHING INDEPENDENCE IN YOUR CAREER: INSIGHTS FROM OUR FELLOWS No matter your career stage, from developing yourself in a specific field of research to bringing your independent research group to international recognition, we can support you. Dr Sean Lim and Dr Charlie Massie are both at the 'Establish independence' stage in our Competency Framework for Fellowships. In our latest case studies, the 2 fellows discuss how they demonstrated in their application the skills and experience expected at this this point in their careers: |
|
|---|
|  TACKLING THE KEY CHALLENGES IN CANCER DRUG DISCOVERY Cancer drug discovery is filled with challenges. These can range from the issue of therapeutic resistance to the fact that important drivers of cancer are often the hardest to drug. The Drug Discovery Unit (DDU) at CRUKs Beatson Institute aims to tackle these hurdles through a collaborative approach that involves working with many different groups of scientists. Heather McKinnon, joint head of the Beatson DDU, chaired the Oncology in Drug Discovery track at ELRIGs Drug Discovery 2019 conference. In this blog, Heather shares her insights on how CRUK is tackling some of the toughest problems in cancer drug discovery head-on. |
|
|---|
|
|---|
|
|
 REPLACING, REFINING AND REDUCING ANIMALS IN RESEARCH: SKILLS AND KNOWLEDGE TRANSFER GRANTS CRUK-funded researchers are eligible to apply for the 2019/2020 CRUK/NC3Rs Skills & Knowledge Transfer scheme. These awards are jointly funded by ourselves and the NC3Rs, offering grants of up to 75,000 to support the wider adoption and transfer of 3Rs approaches between different laboratories and institutions working in cancer research. The deadline for submission of outline applications is 27 November 2019. |
|
|---|
|  DONT MISS OUT: CRICK CLINICAL FELLOWSHIP APPLICATIONS CLOSING SOON Applications for the Crick 2020 doctoral clinical fellow programme are soon coming to a close. The fellowships are open to talented and motivated clinicians who are passionate about research, have a strong academic track record and have the potential to pursue a career as an academic clinician. Fellows will carry out exciting research projects for 3 years while following the Crick's clinical PhD programme. Deadline: 13 November 2019 |
|
|---|
|
|---|
|
|
| | PRODUCING PRECLINICAL DATA ON COLORECTAL CANCER USING MODELLING SYSTEMS The ACRCelerate Colorectal Cancer Stratified Medicine Network, led by Prof Owen Sansom at the CRUK Beatson Institute in Glasgow, is a Europe-wide consortium of basic and clinical scientists at the forefront of colorectal cancer research. The overarching aim of the ACRCelerate project is to generate robust and reproducible preclinical data, using a suite of state-of-the art preclinical models, to de-risk future clinical trials via patient stratification. Over 2426 November, the network is holding a workshop and a training day. The workshop will see the group share their findings and ideas, and the training day will examine different preclinical modelling systems. |
|
|---|
|
|---|
|
|
| | | LONDON, UK 07 November 2019 |
|
|---|
|
|---|
| | | UNIVERSITY COLLEGE LONDON, LONDON, UK 12 November 2019 |
|
|---|
|
|---|
| | | LONDON, UK 25 November 2019 |
|
|---|
|
|---|
| | | SAN DIEGO, CALIFORNIA, USA 24 April 2020 |
|
|---|
|
|---|
| | | CHICAGO, ILLINOIS, USA 29 May 2020 |
|
|---|
|
|---|
|
|
| Been forwarded this email? Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
